Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Universe Pharmaceuticals (UPC) over the last 6 years, with Q3 2025 value amounting to $33.6 billion.

  • Universe Pharmaceuticals' Cash & Equivalents rose 53558.1% to $33.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $33.6 billion, marking a year-over-year increase of 53558.1%. This contributed to the annual value of $29.5 billion for FY2025, which is 45811.38% up from last year.
  • Latest data reveals that Universe Pharmaceuticals reported Cash & Equivalents of $33.6 billion as of Q3 2025, which was up 53558.1% from $5.3 billion recorded in Q3 2024.
  • In the past 5 years, Universe Pharmaceuticals' Cash & Equivalents registered a high of $33.6 billion during Q3 2025, and its lowest value of $5711.5 during Q3 2023.
  • Moreover, its 5-year median value for Cash & Equivalents was $13.6 million (2022), whereas its average is $5.6 billion.
  • As far as peak fluctuations go, Universe Pharmaceuticals' Cash & Equivalents tumbled by 9999.99% in 2023, and later skyrocketed by 9253751473.87% in 2024.
  • Quarter analysis of 5 years shows Universe Pharmaceuticals' Cash & Equivalents stood at $8.1 million in 2021, then skyrocketed by 70604.67% to $5.7 billion in 2022, then plummeted by 100.0% to $5711.5 in 2023, then surged by 92537514.74% to $5.3 billion in 2024, then soared by 535.58% to $33.6 billion in 2025.
  • Its Cash & Equivalents stands at $33.6 billion for Q3 2025, versus $5.3 billion for Q3 2024 and $5.3 million for Q1 2024.